The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Open accessAbstract
BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were the composite of asymptomatic proximal or symptomatic venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (superiority test). The principal safety outcome was the composite of major or clinically relevant nonmajor bleeding. RESULTS: A total of 8101 patients underwent randomization. A primary efficacy outcome event occurred in 78 of 2938 patients (2.7%) receiving rivaroxaban and 82 of 2993 patients (2.7%) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0.97; 95% confidence interval [CI], 0.71 to 1.31; P=0.003 for noninferiority) and in 131 of 2967 patients (4.4%) who received rivaroxaban and 175 of 3057 patients (5.7%) who received enoxaparin followed by placebo at day 35 (relative risk, 0.77; 95% CI, 0.62 to 0.96; P=0.02). A principal safety outcome event occurred in 111 of 3997 patients (2.8%) in the rivaroxaban group and 49 of 4001 patients (1.2%) in the enoxaparin group at day 10 (P<0.001) and in 164 patients (4.1%) and 67 patients (1.7%) in the respective groups at day 35 (P<0.001). CONCLUSIONS: In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Samama, M. M., Cohen, A. T., Darmon, J.-Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.-G., Turpie, A. G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411103 · Cited by 1,584
Self-citationLeizorovicz, A., Cohen, A. T., Turpie, A. G. G., Olsson, C.-G., Vaitkus, P. T., & Goldhaber, S. Z. (2004) · Circulation · doi:10.1161/01.cir.0000138928.83266.24 · Cited by 955
Self-citationCohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G. G., Egberts, J. F. M., & Lensing, A. W. A. (2006) · BMJ · doi:10.1136/bmj.38733.466748.7c · Cited by 857
Self-citationSamama, M.-M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3415 · Cited by 695
Eyer, M. M., Amama, M. I. S., Lexander, A., Ohen, T. H. C., Ean, J., Armon, V. D., Esjardins, L. O. D., Ldor, A. M. E., Anbon, C. H. J., Eizorovicz, A. L. L., et al. (1999) · Cited by 623
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Goldhaber, S. Z., Leizorovicz, A., Kakkar, A. K., Haas, S. K., Merli, G., Knabb, R. M., & Weitz, J. I. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110899 · Cited by 547
Self-citationDentali, F., Douketis, J. D., Gianni, M., Lim, W., & Crowther, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00007 · Cited by 544
Alikhan, R., Cohen, A. T., Combe, S., Samama, M. M., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Olsson, C.-G., & Turpie, A. G. G. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.963 · Cited by 481
Self-citationFactors at Admission Associated With Bleeding Risk in Medical Patients
Decousus, H., Tapson, V. F., Bergmann, J.-F., Chong, B. H., Froehlich, J. B., Kakkar, A. K., Merli, G. J., Monreal, M., Nakamura, M., Pavanello, R., et al. (2011) · Chest · doi:10.1378/chest.09-3081 · Cited by 431
Self-citationVenous Thromboembolism in the Outpatient Setting
Spencer, F. A., Lessard, D., Emery, C., Reed, G., & Goldberg, R. J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.14.1471 · Cited by 401
Hull, R. D., Schellong, S. M., Tapson, V. F., Monreal, M., Samama, M.-M., Nicol, P., Vicaut, E., Turpie, A. G. G., Yusen, R. D., & study*, F. T. E. (. P. F. V. T. I. A. I. M. P. W. P. I. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-1-201007060-00004 · Cited by 384
Self-citationNadroparin in the Prevention of Deep Vein Thrombosis in Acute Decompensated COPD
FRAISSE, F., HOLZAPFEL, L., COULAND, J.-M., SIMONNEAU, G., BEDOCK, B., FEISSEL, M., HERBECQ, P., PORDES, R., POUSSEL, J.-F., ROUX, L., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9807025 · Cited by 300
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
Alikhan, R., Arcelus, J. I., Bergmann, J.-F., Haas, S., Merli, G. J., Spyropoulos, A. C., Tapson, V. F., Turpie, A. G. G., & Cohen, A. T. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-06-0385 · Cited by 249
Self-citationCohen, A. T., Spiro, T. E., Buller, H. R., Haskell, L. P., Hu, D., Hull, R. D., Mebazaa, A., Merli, G. J., Schellong, S., Spyropoulos, A. C., et al. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0549-x · Cited by 120
Self-citation
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.031 · Cited by 2,885
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Kaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Self-citationThrombosis: A Major Contributor to Global Disease Burden
Raskob, G. E., Angchaisuksiri, P., Blanco, A. N., Buller, H., Gallus, A., Hunt, B. J., Hylek, E. M., Kakkar, A., Konstantinides, S. V., McCumber, M., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304488 · Cited by 1,158
Metadata
- Authors
- Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., & Tapson, V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-07
- Volume
- 368
- Issue
- 6
- Pages
- 513-523
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159407715
- Cited by
- 607
- References
- 17
- FWCI
- 54.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.